PDL BIOPHARMA, INC.

Form 3 June 26, 2007

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 3 Washington, D.C. 20549

**OMB APPROVAL** 

**OMB** Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

**SECURITIES** Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

Person \*

A Shumate Cynthia Lynn

(Last)

(First)

(Middle)

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

Statement

(Month/Day/Year)

06/20/2007

PDL BIOPHARMA, INC. [PDLI]

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

VP Legal Affrs, Secy & CCO

5. If Amendment, Date Original

Filed(Month/Day/Year)

C/O PDL BIOPHARMA. INC., Â 34801 CAMPUS DRIVE

(Street)

Director \_X\_\_ Officer

10% Owner Other (give title below) (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line) \_X\_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

FREMONT, Â CAÂ 94555

(City) (State) (Zip)

1. Title of Security (Instr. 4)

2. Amount of Securities

Beneficially Owned

(Instr. 4)

Ownership Form:

Table I - Non-Derivative Securities Beneficially Owned

4. Nature of Indirect Beneficial

Ownership (Instr. 5)

Direct (D) or Indirect (I) (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

Date

Exercisable

3. Title and Amount of Securities Underlying Derivative Security

4. Conversion or Exercise Price of

Derivative

5. Ownership Form of Derivative Security:

6. Nature of Indirect Beneficial Ownership (Instr. 5)

(Instr. 4)

Direct (D) or Indirect

Expiration Date

Title

Amount or Security Number of Shares

(I)

						(Instr. 5)		
Stock Option (Right to Buy)	(1)	04/12/2014	Common Stock	105,000	\$ 25.5	D	Â	
Stock Option (Right to Buy)	(2)	07/20/2013	Common Stock	26,500	\$ 17.13	D	Â	
Stock Option (Right to Buy)	(3)	07/23/2014	Common Stock	3,850	\$ 15.25	D	Â	
Stock Option (Right to Buy)	(4)	07/13/2012	Common Stock	32,000	\$ 21.73	D	Â	

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
<b></b>	Director	10% Owner	Officer	Other		
Shumate Cynthia Lynn C/O PDL BIOPHARMA, INC. 34801 CAMPUS DRIVE FREMONT Â CAÂ 94555	Â	Â	VP Legal Affrs, Secy & CCO	Â		

## **Signatures**

/s/ Cynthia Shumate	06/26/200		
**Signature of	Date		

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This Option was vested with respect to 83,125 shares on June 20, 2007 and vests monthly with respect to 2,187 shares.
- (2) This Option was vested with respect to 4,531 shares on June 20, 2007 and vests monthly with respect to 594 shares.
- (3) This Option was vested with respect to 3,120 shares on June 20, 2007 and vests monthly with respect to 150 shares.
- (4) This Option was vested with respect to 15,333 shares on June 20, 2007 and vests monthly with respect to 667 shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2